Farletuzumab, an anti-folate receptor α antibody, does not block binding of folate or anti-folates to receptor nor does it alter the potency of anti-folates in vitro-Reference-Cited by-同舟云学术

Farletuzumab, an anti-folate receptor α antibody, does not block binding of folate or anti-folates to receptor nor does it alter the potency of anti-folates in vitro

Published:2012-05-27 Issue:1 Volume:70 Page:113-120
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Kamen B. A.,Smith A. K.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-012-1890-2.pdf

Reference21 articles.

1. Fox JT, Stover PJ (2008) Folate-mediated one-carbon metabolism. In: Litwack G (ed) Vitamins and hormones: folic acid and folates (vol 79). Elsevier, Philadelphia, pp 1–29

2. Kamen BA, Cole P, Bertino JR (2006) Chemotherapeutic agents: folic acid antagonists. In: Holland JF, Frei E, Bast RC, Kufe DW, Morton DL, Weichselbaum RR (eds) Cancer medicine. Williams and Wilkins, Philadelphia, pp 648–660

3. Westerhof GR, Schornagel JH, Kathmann I et al (1995) Carrier- and receptor mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activity. Mol Pharmacol 48:459–471

4. Elnakat H, Ratnam M (2004) Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy. Adv Drug Deliv Rev 56:1067–1084

5. Leamon CP, Reddy JA (2004) Folate-targeted chemotherapy. Adv Drug Deliv Rev 56:1127–1141

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An overview of nanoparticles in drug delivery: Properties and applications;South African Journal of Chemical Engineering;2023-10

2. Immunotherapy in gynecologic malignancies;DiSaia and Creasman Clinical Gynecologic Oncology;2023

3. Discovery of 6-substituted thieno[2,3-d]pyrimidine analogs as dual inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase in de novo purine nucleotide biosynthesis in folate receptor expressing human tumors;Bioorganic & Medicinal Chemistry;2021-05

4. To Conjugate or to Package? A Look at Targeted siRNA Delivery Through Folate Receptors;Nucleic Acid Therapeutics;2021-02-01

5. Discovery of amide-bridged pyrrolo[2,3-d]pyrimidines as tumor targeted classical antifolates with selective uptake by folate receptor α and inhibition of de novo purine nucleotide biosynthesis;Bioorganic & Medicinal Chemistry;2019-12